Literature DB >> 25619837

A stress-induced early innate response causes multidrug tolerance in melanoma.

D Ravindran Menon, S Das, C Krepler, A Vultur, B Rinner, S Schauer, K Kashofer, K Wagner, G Zhang, E Bonyadi Rad, N K Haass, H P Soyer, B Gabrielli, R Somasundaram, G Hoefler, M Herlyn, H Schaider.   

Abstract

Correction to: Oncogene (2015) 34, 4448–4459; doi:10.1038/onc.2014.372; published online 24 November 2014. In this article, published online 24 November 2014, the authors have noticed that the latest supplementary information was not used. The corrected supplementary information (Supplementary Materials) appears online together with this corrigendum. The authors would like to apologise for any inconvenience this may cause

Entities:  

Year:  2015        PMID： 25619837     DOI： 10.1038/onc.2014.432

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  18 in total

1.  Dynamic tumor heterogeneity in melanoma therapy: how do we address this in a novel model system?

Authors:  Nikolas K Haass
Journal:  Melanoma Manag       Date:  2015-05-18

2.  A Nonquiescent "Idling" Population State in Drug-Treated, BRAF-Mutated Melanoma.

Authors:  B Bishal Paudel; Leonard A Harris; Keisha N Hardeman; Arwa A Abugable; Corey E Hayford; Darren R Tyson; Vito Quaranta
Journal:  Biophys J       Date:  2018-03-27       Impact factor: 4.033

3.  KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations.

Authors:  Xiaoni Liu; Shang-Min Zhang; Marcus W Bosenberg; Qin Yan; Meaghan K McGeary; Irina Krykbaeva; Ling Lai; Daniel J Jansen; Stephen C Kales; Anton Simeonov; Matthew D Hall; Daniel P Kelly
Journal:  Mol Cancer Ther       Date:  2018-12-06       Impact factor: 6.261

Review 4.  Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer.

Authors:  Marilyne Labrie; Joan S Brugge; Gordon B Mills; Ioannis K Zervantonakis
Journal:  Nat Rev Cancer       Date:  2022-03-09       Impact factor: 69.800

Review 5.  Nivolumab in combination with ipilimumab for the treatment of melanoma.

Authors:  Rajasekharan Somasundaram; Meenhard Herlyn
Journal:  Expert Rev Anticancer Ther       Date:  2015       Impact factor: 4.512

6.  Microenvironment-Driven Resistance to BRAF Inhibition Comes of Age.

Authors:  Dinoop Ravindran Menon; Helmut Schaider
Journal:  J Invest Dermatol       Date:  2015-12       Impact factor: 8.551

Review 7.  Phenotype plasticity as enabler of melanoma progression and therapy resistance.

Authors:  Imanol Arozarena; Claudia Wellbrock
Journal:  Nat Rev Cancer       Date:  2019-06-17       Impact factor: 60.716

8.  Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance.

Authors:  Michael P Smith; Claudia Wellbrock
Journal:  Clin Cancer Res       Date:  2016-10-19       Impact factor: 12.531

Review 9.  Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells.

Authors:  Nabanita Mukherjee; Josianna V Schwan; Mayumi Fujita; David A Norris; Yiqun G Shellman
Journal:  J Invest Dermatol       Date:  2015-05-07       Impact factor: 8.551

Review 10.  Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas.

Authors:  Jiri Vachtenheim; Lubica Ondrušová
Journal:  Life (Basel)       Date:  2021-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.